Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Tolerability of PF-08057418 in Healthy Adult Participants
NCT07575906Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Placebo with PF-08057418 (2 arms). Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 10 weeks. Started May 2026; status: completed.
02
Drugs
PF-08057418
Beyond the preview
Go deeper on NCT07575906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07575906.